CASI Pharmaceuticals Inc (CASI) was Initiated by Maxim Group to “Buy” and the brokerage firm has set the Price Target at $4. Maxim Group advised their investors in a research report released on Sep 22, 2016.
CASI Pharmaceuticals Inc closed down -0.02 points or -1.83% at $1.07 with 7,582 shares getting traded on Tuesday. Post opening the session at $1.09, the shares hit an intraday low of $1.07 and an intraday high of $1.14 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
In a different news, on Jan 21, 2016, Ken Keyong Ren (CEO) purchased 15,000 shares at $0.73 per share price. According to the SEC, on Jan 21, 2016, Ken Ren (CEO) purchased 15,000 shares at $0.73 per share price. On Jan 21, 2016, Cynthia W. Hu (COO) purchased 16,800 shares at $0.73 per share price, according to the Form-4 filing with the securities and exchange commission.
CASI Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the acquisition development and commercialization of therapeutics for cancer and other medical needs. Its product pipeline includes ENMD-2076 ZEVALIN MARQIBO CE Melphalan and 2ME2 (2-methoxyestradial). Its lead internal drug candidate is ENMD-2076 is a selective Aurora A and angiogenic kinase inhibitor for the treatment of cancer. ZEVALIN is indicated for patients with relapsed or refractory low-grade or follicular B-cell non-Hodgkin’s lymphoma. MARQIBO is indicated for the treatment of Philadelphia chromosome-negative acute lymphoblastic leukemia. Captisol Enabled melphalan is being investigated and is intended to be used as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma. 2ME2 (2-methoxyestradiol) is an orally active compound that has anti-proliferative anti-angiogenic and anti-inflammatory properties under reformulation development.